Reselute’s mission is to provide innovative drug delivery solutions for the treatment of orthopedic infections to accelerate treatment and improve patient care. Reselute was founded in Durham, NC in 2021 by experienced serial medtech entrepreneurs, Drs. Cambre Kelly and Ken Gall. The company’s proprietary technology was developed in the Gall lab at Duke University, designed to deliver therapeutics where and when they are needed, locally to the surgical site over a sustained period. The company’s first product, ReselutionTM Intramedullary System received Breakthrough Device Designation from the FDA and is anticipated to start first in human clinical trials in the US in 2026. Reselute has been supported by a number of NSF and NIH grant awards, as well as equity financing.